Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of rifampicin on single-dose tasquinimod pharmacokinetics in healthy volunteers
NL-OMON35265Phase 1Active, not recruiting
- Sponsor
- PRA Health Sciences
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tasquinimod and rifampicin in prostate cancer (PCa), sponsored by PRA Health Sciences. Primary endpoints: Maximum plasma concentration of tasquinimod, Area under the plasma concentration-time curve from time 0 to time t and 1 more. Started Jan 2012; status: active, not recruiting.
02
Drugs
tasquinimodrifampicin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON35265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35265.